Advertisement

Topics

Positive results for Mapi Pharma's Copaxone rival

05:59 EDT 1 Nov 2017 | Globes

The treatment is designed to be taken just once monthly in contrast to Teva's multiple sclerosis treatment, which must be administered twice weekly.

Original Article: Positive results for Mapi Pharma's Copaxone rival

NEXT ARTICLE

More From BioPortfolio on "Positive results for Mapi Pharma's Copaxone rival"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...